MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Search

PerkinElmer Inc

Fermé

SecteurSoins de santé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

-8.6M

47M

Ventes

-21M

699M

P/E

Moyenne du Secteur

50.057

88.032

BPA

0.4

Rendement du dividende

0.29

Marge bénéficiaire

6.675

Employés

11,000

EBITDA

-14M

181M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+14.96% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.29%

2.26%

Prochains Résultats

30 janv. 2026

Date du Prochain Détachement de Dividende

16 janv. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-5.8M

11B

Ouverture précédente

0

Clôture précédente

0

Sentiment de l'Actualité

By Acuity

40%

60%

114 / 374 Classement par Healthcare

PerkinElmer Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 janv. 2026, 22:45 UTC

Principaux Mouvements du Marché

GH Research Shares Up, Plans to Provide Update on New Drug Application

2 janv. 2026, 22:13 UTC

Market Talk
Résultats

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

2 janv. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2 janv. 2026, 21:07 UTC

Résultats

Tesla Stock Pops and Drops After Fourth-Quarter Deliveries. -- Barrons.com

2 janv. 2026, 20:09 UTC

Market Talk

Oil Futures Slip in First Trading Day of the Year -- Market Talk

2 janv. 2026, 19:48 UTC

Market Talk

U.S. Natural Gas Futures Kick Off 2026 With A Loss -- Market Talk

2 janv. 2026, 18:53 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 janv. 2026, 18:53 UTC

Market Talk

Mexico PMIs Show Manufacturing Weakness in December -- Market Talk

2 janv. 2026, 17:56 UTC

Market Talk
Acquisitions, Fusions, Rachats

Meta's Manus Acquisition May Help Fill AI Monetization Gap -- Market Talk

2 janv. 2026, 17:50 UTC

Market Talk

Apparel Industry Seen With Strength Across Income Levels -- Market Talk

2 janv. 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2 janv. 2026, 16:33 UTC

Market Talk

Remittances to Mexico Fell 5.7% in November -- Market Talk

2 janv. 2026, 16:18 UTC

Market Talk

Tesla Dethroned as World's Largest EV Maker -- Market Talk

2 janv. 2026, 15:48 UTC

Résultats

Software Has Been Battered by AI. Shopify, Veeva, and 3 More Stocks to Play a Turnaround. -- Barrons.com

2 janv. 2026, 15:17 UTC

Market Talk

Tesla Expected to Make Its Switch to Robotics, AI in 2026 -- Market Talk

2 janv. 2026, 15:01 UTC

Market Talk

Sable Seen Nearing Production Relaunch After Court Ruling -- Market Talk

2 janv. 2026, 15:00 UTC

Résultats

The Maker of Biscoff Cookies Bets on a Global Expansion -- WSJ

2 janv. 2026, 14:56 UTC

Market Talk

Tesla's Sales Drop Was Better Than Feared -- Market Talk

2 janv. 2026, 14:20 UTC

Market Talk

Capstone Copper's Mantoverde Strike Could Be Costly -- Market Talk

2 janv. 2026, 14:20 UTC

Market Talk

Global Equities Roundup: Market Talk

2 janv. 2026, 14:13 UTC

Market Talk

Oil Futures Open Year Lower on Oversupply Concerns -- Market Talk

2 janv. 2026, 13:39 UTC

Market Talk

U.S. Natural Gas Futures Open Year Lower -- Market Talk

2 janv. 2026, 13:01 UTC

Market Talk
Acquisitions, Fusions, Rachats

Unicredit Could Buy Delfin's BMPS Stake, Launch Full Takeover, Equita Says -- Market Talk

2 janv. 2026, 12:45 UTC

Market Talk

Emerging-Market Dollar Bonds Record Strong Returns in 2025 -- Market Talk

2 janv. 2026, 11:48 UTC

Market Talk

European Gas Climbs as Cold Weather Bites -- Market Talk

2 janv. 2026, 11:36 UTC

Market Talk

Treasury Yields, Dollar Edge Higher as Near-Term Fed Rate Cut Looks Unlikely -- Market Talk

2 janv. 2026, 11:30 UTC

Market Talk

Copper Rally Continues, Spurred by Supply Shocks -- Market Talk

2 janv. 2026, 11:29 UTC

Market Talk

Dollar Rises After Posting Worst Year Since 2017 -- Market Talk

2 janv. 2026, 11:15 UTC

Market Talk

Global Energy Roundup: Market Talk

Comparaison

Variation de prix

PerkinElmer Inc prévision

Objectif de Prix

By TipRanks

14.96% hausse

Prévisions sur 12 Mois

Moyen 111.22 USD  14.96%

Haut 123 USD

Bas 100 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

5

Achat

5

Maintien

0

Vente

Sentiment

By Acuity

114 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat